← Leaderboards
Chi Li
University Of Pennsylvania
$3,939,189
Attributed
$4,337,017
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $621.9K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,337,017 · 10
By mechanism
R01$1,540,461 · 1
P20$1,213,962 · 6
R21$795,656 · 2
K01$786,938 · 1
Top collaborators
- Kavitha Yaddanapudi3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Michael L. Atchison$24,976,166
- Felice Elefant$4,943,868
- Stephen M Hahn$5,432,347
- Qin Yu$7,039,104
- Allyson Elizabeth Lieberman$110,782
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCessation Of LifeDesignApoptosisPathway InteractionsNeoplastic CellPropertyIn VitroCellsMolecularResistanceMediatingMembraneCell DeathMitochondriaEndoplasmic ReticulumSignal TransductionPlayProgramsGrantOrganellesProtein FamilyApoptoticPro-Apoptotic Protein
Grant awards (21)
A Stem Cell Based Exosomal Vaccine for the Prevention of Cancer$173,764
R21 · FY2024 · CA
A lung cancer vaccine based on exosomes of induced pluripotent stem cells$402,401
R21 · FY2023 · CA · contact PI
A Stem Cell Based Exosomal Vaccine for the Prevention of Cancer$219,491
R21 · FY2023 · CA
Activating Bax as a therapeutic strategy for lung cancer$309,952
R01 · FY2017 · CA · contact PI
Activating Bax as a therapeutic strategy for lung cancer$309,952
R01 · FY2016 · CA · contact PI
Activating Bax as a therapeutic strategy for lung cancer$309,952
R01 · FY2015 · CA · contact PI
Activating Bax as a therapeutic strategy for lung cancer$300,653
R01 · FY2014 · CA · contact PI
Activating Bax as a therapeutic strategy for lung cancer$309,952
R01 · FY2013 · CA · contact PI
COBRE PROJ 6: PROGRAMMED DEATH PATHWAY INITIATED FROM THE ENDOPLASMIC RETICULUM$239,806
P20 · FY2011 · RR · contact PI
COBRE PROJ 6: PROGRAMMED DEATH PATHWAY INITIATED FROM THE ENDOPLASMIC RETICULUM$242,228
P20 · FY2010 · RR · contact PI
Regulation of apoptosis by Bcl-XL, Bak and Bax$155,250
K01 · FY2009 · CA · contact PI
COBRE PROJ 6: PROGRAMMED DEATH PATHWAY INITIATED FROM THE ENDOPLASMIC RETICULUM$117,511
P20 · FY2009 · RR · contact PI
Regulation of apoptosis by Bcl-XL, Bak and Bax$50,000
K01 · FY2009 · CA · contact PI
COBRE PROJ 6: PROGRAMMED DEATH PATHWAY INITIATED FROM THE ENDOPLASMIC RETICULUM$215,136
P20 · FY2008 · RR · contact PI
Regulation of apoptosis by Bcl-XL, Bak and Bax$155,250
K01 · FY2008 · CA · contact PI
Regulation of apoptosis by Bcl-XL, Bak and Bax$155,250
K01 · FY2007 · CA · contact PI
COBRE PROJ 6: PROGRAMMED DEATH PATHWAY INITIATED FROM THE ENDOPLASMIC RETICULUM$154,004
P20 · FY2007 · RR · contact PI
COBRE:LOUISVILLE RES FOUND INC: P2: [CHI LI (SPID 0013) ON SINCE 02/01/06]$245,277
P20 · FY2006 · RR · contact PI
Regulation of apoptosis by Bcl-XL, Bak and Bax$132,516
K01 · FY2006 · CA · contact PI
Regulation of apoptosis by Bcl-XL, Bak and Bax$86,608
K01 · FY2005 · CA
Regulation of apoptosis by Bcl-XL, Bak and Bax$52,064
K01 · FY2005 · CA